# EssilorLuxottica account plan

> EssilorLuxottica makes and sells lenses, frames, smart glasses and eye-care technology, with €28,491m of 2025 revenue and 200,000+ employees.

## At a glance

EssilorLuxottica is a vertically integrated vision care and eyewear group, formed in 2018 from Essilor (lenses) and Luxottica (frames and retail), that designs, manufactures and sells lenses, frames, sunglasses, smart glasses and, increasingly, medical technology. It serves 300,000+ wholesale customers and runs 17,750 stores at end-2025 in more than 150 countries, with brands including Ray-Ban, Oakley, Varilux, Transitions and licences such as Prada and Chanel. FY2025 revenue was €28,491m, +11.2% at constant exchange rates, with adjusted operating profit of €4,459m (15.7% of revenue) and net profit attributable of €2,315m. The group has 200,000+ employees. It is listed on Euronext Paris (CAC 40, Euro Stoxx 50), with Delfin, the Del Vecchio family holding, as parent company holding 32.4% of the capital.

## Business units

- **Professional Solutions (wholesale)** (48% of 2025 revenue (€13,600m)): Supplies lenses, frames, instruments, contact lenses and services to 300,000+ customers, from independent opticians and chains to distributors, department stores and now ophthalmologists and hospitals. Revenue grew 12.2% at constant FX in 2025, with North America up more than 40% in Q4 on AI glasses; growth slowed to 4.9% in Q2 2026.
- **Direct to Consumer (retail and e-commerce)** (52% of 2025 revenue (€14,891m)): Runs banners such as Sunglass Hut, LensCrafters, Vision Express, Pearle and GrandVision, e-commerce sites such as Ray-Ban.com, the EyeMed managed vision care business with 85 million members, and almost 90 eye clinics in six European markets. Comparable-store sales rose 7% in 2025 and 7.5% in H1 2026; store count reached 19,686 at 30 June 2026 after the Top Charoen deal.
- **Smart eyewear and wearables**: Ray-Ban Meta, Oakley Meta and Meta Ray-Ban Display AI glasses with Meta, plus Nuance Audio hearing glasses launched in 12 markets and 15,000 stores. It was the dominant driver of H2 2025, and AI glasses revenue was almost doubling in Q2 2026.
- **Medical technologies and clinics**: A new med-tech platform built from Heidelberg Engineering (OCT imaging), RetinAI, Cellview Imaging, Espansione and the Optegra and Signifeye clinics, aiming at an end-to-end patient journey from screening to diagnostics, therapy and surgery.

## Strategic priorities

- **Med-tech transformation**: The group is evolving "from a 'traditional' optical leader into a med-tech, science and data-driven company", building clinics, diagnostics and AI eye-care software.
- **AI glasses with Meta**: Extend AI glasses across lifestyle, sport and health; smart-glasses production capacity was being expanded to 10 million units a year by the end of 2025, and a $299 Meta Glasses collection launched in June 2026.
- **Myopia management**: Scale the Stellest platform toward prevention: Stellest received FDA De Novo authorisation in September 2025 and launched in the US in Q4 2025; the myopia portfolio grew 24% in Q2 2026.
- **AI-native organisation**: Demand forecasting, store associate co-pilots and preparation for agentic commerce from 2026, under a Responsible Use of AI policy.
- **Five-year outlook**: Over the next five years, on average and at constant exchange rates, "solid growth" of total revenue with broadly aligned growth of adjusted operating profit.

## Latest results

In H1 2026 revenue was €14,818m, up 9.7% at constant exchange rates, with Q2 at +8.7% after +10.8% in Q1 "in a more unsettled macro environment". Adjusted operating profit rose 15.0% at constant FX to €2,751m, an 18.6% margin, helped by better wearables profitability and a net positive tariff impact after the US Supreme Court ruled the 2025 additional tariffs unlawful. Direct to Consumer (€8,001m, +11.4%) outpaced Professional Solutions (€6,817m, +7.8%), and Asia-Pacific grew fastest at +13.4%. Net debt rose to €13.39bn (2.0x EBITDA) after dividends, buybacks and acquisitions. The five-year outlook was unchanged.

## Investments and deals

- **Med-tech and clinic acquisitions**: 2025 deals included Optegra (70+ eye hospitals and clinics, closed 1 Oct 2025), RetinAI, Cellview Imaging, Espansione and Pulse Audition; Signifeye closed in February 2026. Financial investments net of cash were €911m in 2025.
- **Retail expansion in Asia and the US**: A stake in Top Charoen, Thailand's largest optical chain with almost 2,000 stores, closed 2 April 2026, and Pearle Vision acquired West Point Optical Group (90 centres) in June 2026.
- **Capex and wearables capacity**: Capex was €1,525m (5.4% of revenue) in 2025; wearables capacity was expanded in Dongguan, and the Agordo plant in Italy will host the first wearables production lines from early 2027.
- **Applied Materials partnership**: A long-term joint development agreement signed in June 2026 covers waveguides, adaptive lenses and AR optics, with a collaboration lab in Silicon Valley.
- **Share buybacks**: A buyback of up to 5,000,000 shares started 13 February 2026; €969m was spent on 4,561,701 shares in H1 2026.

## Challenges and risks

- **Tariffs and margin dilution**: US tariffs from Q2 2025 and the wearables mix cut the adjusted gross margin to 60.9% in 2025 from 63.5% in 2024.
- **Big-tech competition in smart eyewear**: The URD names big-tech entry into smart eyewear as a top risk; Reuters reported the share price had lost more than 40% since its November record as investors worried about competition.
- **Legitimacy in med-tech**: The URD states the group does not yet have the same expertise and legitimacy in med-tech as in its core business.
- **Cybersecurity and data privacy**: Cybersecurity, IT systems and data privacy are ranked among the most severe risks for a group serving more than half a billion patients and consumers a year.
- **Geopolitics and rising debt**: Middle East tensions weighed on Q2 2026 EMEA wholesale, Mainland China is 4% of revenue, and net debt rose to €13.39bn in H1 2026.

## What leadership says

> "Our goal is to replace, by simplifying its functions, the current smartphone." — Francesco Milleri, Chairman and CEO, Il Foglio interview, 2025-04-15

> "We were too big to stay confined to this small market" — Francesco Milleri, Chairman and CEO, Remarks at the AGM reported by Reuters, 2026-04-28

> "A few big players have made product announcements that generated a lot of interest, but we have not yet seen real competing products on the market." — Francesco Milleri, Chairman and CEO, Remarks at the AGM reported by Reuters, 2026-04-28

> "Only a collaborative model, a network company, can keep leadership in innovation and technology." — Francesco Milleri, Chairman and CEO, Bloomberg Línea, 2025-10-10


## Where a supplier can help

- **Clinical software and diagnostics**: Tied to the med-tech transformation and the stated gap in med-tech legitimacy: clinical systems, imaging, AI diagnostics and regulatory expertise help build out the clinic network.
- **Wearables components and manufacturing**: Tied to the AI glasses priority and wearables capacity investment: optics, display, chip, battery and assembly suppliers serve new lines in Dongguan and Agordo.
- **Retail AI and agentic commerce**: Tied to the AI-native organisation priority: demand forecasting, store associate co-pilots and agentic commerce tools across 19,686 stores and e-commerce.
- **Cyber security and data privacy**: Tied to the cybersecurity and privacy challenge, which grows as clinics and connected glasses add health and personal data.
- **Integration support for acquired retail and clinics**: Tied to the Top Charoen, West Point Optical and clinic acquisitions: post-merger IT, store systems and process integration.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [2025 Universal Registration Document](https://www.essilorluxottica.com/caas/v1/media/284322/data/f95ef2e9903624401eeb5d083d1061bc/essilorluxottica-urd-en-2025-mel-march06.pdf)

Annual report · 2026-03-06

- EssilorLuxottica (Paris-listed, CAC 40 and Euro Stoxx 50; parent company Delfin S.à r.l., Chairman and CEO Francesco Milleri, Deputy CEO Paul du Saillant) is the vertically integrated world leader in vision care, eyewear, smart eyewear and, increasingly, medical technology: 200,000+ employees, 150+ countries, ~18,000 stores (17,750 at end-2025), 150+ brands, 16,500+ patents and designs, 47 mass-production plants (33 lens, 14 frame), 555 prescription labs, 300,000+ wholesale customers, more than half a billion patients and consumers served every year.
- FY2025 revenue €28,491m, +11.2% at constant exchange rates (+7.5% reported), the first double-digit annual growth in the Group's history, with a record Q4 at +18.4%. Adjusted operating profit €4,459m (15.7% of revenue, 16.0% at constant FX, -70bps dilution from US tariffs and the mix of wearables), adjusted net profit €3,157m (+7.2% at constant FX), free cash flow €2,796m (+€383m), net debt €10,853m (1.7x EBITDA). Reported operating profit €3,379m (11.9%), net profit attributable €2,315m.
- Two operating segments: Professional Solutions (wholesale) €13,600m (+12.2% at constant FX) and Direct to Consumer (retail + e-commerce) €14,891m (+10.3%, comparable-store sales +7%, e-commerce up high-teens). By region: North America €12,787m (+11.6%), EMEA €10,779m (+11.8%, first time above €10bn), Asia-Pacific €3,410m (+10.1%), Latin America €1,515m (+7.6%).
- Growth engines: AI glasses with Meta (Ray-Ban Meta Gen 2, Oakley Meta HSTN and Vanguard, Meta Ray-Ban Display with in-lens display at $799), the dominant driver of H2 2025, with North America Professional Solutions up more than 40% in Q4; myopia management (Essilor Stellest, first FDA-authorised myopia-control spectacle lens, Stellest 2.0 in China, Nikon/Kodak DOT lenses worn by over one million children); Nuance Audio hearing glasses (FDA-cleared, 12 markets, 15,000 stores); lens premiumisation (Varilux, Transitions, Crizal, Eyezen, Shamir).
- Strategy rests on three pillars: med-tech, wearables/AI and the brand portfolio. 2025 M&A built a med-tech platform: Optegra (70+ eye hospitals and clinics in the UK, Czech Republic, Poland, Slovakia, Netherlands, closed 1 Oct 2025), Signifeye (15 Belgian clinics, closed Feb 2026), RetinAI (AI eye-care software), Cellview Imaging, Espansione, Pulse Audition, plus vertical-integration deals (PUcore monomers, Automation & Robotics, A-Look retail in Malaysia). Financial investments net of cash €911m; capex €1,525m (5.4% of revenue).
- New long-term outlook: over the next five years, on average and at constant exchange rates, "solid growth" of total revenue with broadly aligned growth of adjusted operating profit. Dividend proposed for 2025: €4.00 per share (approved April 2026). A new share buyback of up to 5,000,000 shares started 13 February 2026.
- Risks rated highest: cybersecurity/IT, data privacy, political and social environment (US tariffs, Middle East, China at 4% of revenue), competition from big tech in smart eyewear, and the Group's lesser legitimacy in med-tech; gross margin fell to 60.9% adjusted (63.5% in 2024) on tariffs and wearables mix.
- Executives' framing: the Group is evolving "from a 'traditional' optical leader into a med-tech, science and data-driven company", with smart eyewear expected "to redefine personal and wearable computing" and the eye as a window into systemic health (oculomics). A Scientific Advisory Committee of five scientists (Aspect, Figalli, Sahel, Kujawa, Vayena) was created in December 2025.

### [Q2/H1 2026 results press release and First-half 2026 Management Report](https://www.essilorluxottica.com/caas/v1/media/305620/data/94b0317fbbbad9529870391c3799ceea/essilorluxottica-q2h1-2026-press-release-en.pdf)

Interim report · 2026-07-28

- H1 2026 revenue €14,818m, +9.7% at constant exchange rates (+5.7% reported), Q2 €7,692m at +8.7% after +10.8% in Q1, "in a more unsettled macro environment"; all regions and both segments grew.
- Adjusted operating profit €2,751m, +15.0% at constant FX, margin 18.6% (18.9% at constant FX, +80bps); adjusted gross margin 63.5% (+10bps) helped by better wearables profitability and a net positive tariff impact after the US Supreme Court ruled the 2025 additional tariffs unlawful in February 2026; adjusted net profit €1,921m (+13.3%); reported operating profit €2,296m, net profit attributable €1,566m, EPS €3.40 (€3.04).
- Direct to Consumer €8,001m (+11.4%, comparable-store sales +7.5% in H1, +8% in Q2) outpaced Professional Solutions €6,817m (+7.8%, +4.9% in Q2, low-single-digit in North America, EMEA and Latin America, mid-teens in Asia-Pacific).
- Regions H1: North America €6,374m (+9.9%), EMEA €5,785m (+8.7%, Middle East tensions weighed on Q2 wholesale), Asia-Pacific €1,853m (+13.4%, Q2 +17.0% with China, India, Japan and Korea at double digits and Top Charoen consolidated), Latin America €806m (+6.7%).
- Product engines: core eyecare/eyewear mid-single digit; myopia portfolio +24% in Q2 (Stellest ramp-up in the US, Stellest 2.0 and Nikon/Kodak DOT in China); AI glasses "almost doubling" in Q2 revenue, rolled out to Singapore, Japan and South Korea, with Ray-Ban Meta Optics prescription styles (from $499) and the $299 Meta Glasses collection launched in June.
- Free cash flow €1.07bn (€0.96bn), but net debt rose to €13.39bn (2.0x EBITDA LTM of €6,821m) after €1.73bn of dividends (only 9% took shares vs 70% in 2025), €969m of buybacks (4,561,701 shares at €211.51 average) and acquisitions; cash €1.93bn.
- Store count jumped to 19,686 (17,750 at end-2025) with Top Charoen in Thailand (almost 2,000 stores, stake closed 2 April 2026); other deals: Signifeye (Feb 2026), Faro CNC machinery (April), West Point Optical (90 Pearle Vision centres, June); licence with Dolce&Gabbana extended to 2050.
- Strategic moves: long-term joint development agreement with Applied Materials (June 2026) on waveguides, adaptive lenses and AR optics with a lab in Silicon Valley; first wearables production lines in Italy at Agordo from early 2027; a Responsible Use of AI policy.
- Outlook unchanged: over the next five years, solid revenue growth and broadly aligned adjusted operating profit growth at constant exchange rates; Q3 2026 revenue due 20 October 2026.

### [Il Foglio: "Possible innovations and challenges for Italy" - a conversation with Francesco Milleri](https://www.ilfoglio.it/economia/2025/04/15/news/possible-innovations-and-challenges-for-italy-a-conversation-with-francesco-milleri-ceo-of-essilorluxottica--113962)

Executive talk · Francesco Milleri, Chairman and Chief Executive Officer · 2025-04-15

- Wide-ranging interview (Il Foglio, Claudio Cerasa, 15 April 2025; English AI translation) with Francesco Milleri, 66 covering smart glasses, med-tech, chips, data ethics, Italy and Delfin's financial stakes.
- Core bet: "in the digital society, sight and hearing are destined to take on an increasingly central role"; the eye is "the only organ in our body exposed to the outside, easily monitorable", so glasses will unify vision, hearing and voice. Stated goal: "to replace, by simplifying its functions, the current smartphone."
- Smart glasses could carry biometric authentication (iris, jawbone vibration), a payment wallet, car and home controls; Nuance Audio shows optics converging with audiology, and he expects applications in automotive, sports, agriculture, medicine and the space economy.
- Display technology is the real breakthrough to come: research focuses on microLEDs, waveguides, holography and metasurfaces; lamination will embed invisible circuits in lenses; low-power eye-tracking will turn the eye into "a true 'mouse'".
- Med-tech thesis: the eye can reveal Alzheimer's, Parkinson's, metabolic, cardiovascular and kidney conditions; acquisitions of Heidelberg Engineering, Espansione, Pulse Audition and Cellview move the Group "upstream along the entire chain"; surgical suites are being piloted in North American stores; "the longevity economy is destined to drive global trends".
- Silicon: the Group is "already filing patents for innovative low-power chips" and sees "a very profitable business" in custom optics controllers and sensor arrays.
- Data and ethics: the Group serves "over half a billion customers" a year and processes "billions of data points"; it is considering an ethical-scientific committee of international experts; the answer to fragmented privacy regulation is "collaborative rather than competitive models".
- Delfin (32.2% of EssilorLuxottica; stakes in Mediobanca 19.9%, Generali 9.8%, Unicredit 2.7%, MPS 9.78%): "purely financial investments" meant to bring technology and scale to Italian finance; he supports the MPS-Mediobanca operation as "a step to make the financial sector in our country more competitive".

### [Bloomberg Línea: EssilorLuxottica prepares to lead the AI-glasses market with Meta (Milleri on Bloomberg's "Quello che i soldi non dicono" podcast)](https://www.bloomberglinea.com/negocios/essilorluxottica-se-prepara-para-liderar-el-mercado-de-gafas-con-ia-junto-a-meta/)

Executive talk · Francesco Milleri, Chairman and Chief Executive Officer · 2025-10-10

- Bloomberg Línea article (10 October 2025, Spanish) reporting a rare interview Francesco Milleri gave to Bloomberg's Italian podcast "Quello che i soldi non dicono": he is positioning "the world's largest eyewear company" to lead AI glasses, which "could replace smartphones as the next consumer-tech hit".
- Capacity: EssilorLuxottica is expanding smart-glasses production capacity to 10 million units a year by the end of 2025, betting on rising demand; the capacity can also serve other smart glasses and Nuance Audio hearing glasses.
- Milleri: glasses, "for so long considered prostheses and later fashion accessories, are on the way to becoming the central device in people's lives, possibly replacing smartphones"; he foresees "hundreds of millions of interconnected smart glasses... creating immense communities".
- The Meta partnership generated an estimated €365m of revenue in 2024 and could approach €800m in 2025 and exceed €6bn in 2030 in Barclays' most optimistic projections; analysts see the category rising from ~3 million to 60 million units a year by 2035. Meta invested $3.5bn for about 3% of the capital; Zuckerberg unveiled the $799 Meta Ray-Ban Display in September.
- Strategy: use the integrated platform of labs, factories and stores to sell higher-value products (myopia-control lenses, med-tech used in clinical settings, wearables); "only a collaborative model, a network company, can keep leadership in innovation and technology"; investment in medical technology including clinical AI and "even beyond ophthalmology".
- Other points: Supreme acquired in 2024 to reach younger consumers; Armani described only as "a prospect for evolution"; competition from Chinese and US players and uncertain consumer uptake are flagged; market value about €128bn at the time; Milleri, 65, became chairman in 2022 and the market value has more than doubled since.

### [Reuters: EssilorLuxottica's CEO confident the share price will recover over time (remarks at the 28 April 2026 AGM)](https://www.boursorama.com/bourse/actualites/le-directeur-general-d-essilorluxottica-est-convaincu-que-le-cours-de-l-action-remontera-a-terme-96be49ea5c199c79b6e4f837df34790a)

Executive talk · Francesco Milleri, Chairman and Chief Executive Officer · 2026-04-28

- Reuters report (Elisa Anzolin, 28 April 2026, French machine translation on Boursorama) of Francesco Milleri's remarks at EssilorLuxottica's annual general meeting in Paris.
- Milleri said he is confident the shares will regain the ground lost to US tariffs, a weak dollar, spreading military conflicts and competition in smart glasses; the stock had lost more than 40% since its November record, which had been driven by enthusiasm for Ray-Ban Meta AI glasses.
- He acknowledged the shares also suffered from the continued push into medical technology, which he called a necessary transformation: "We were too big to stay confined to this small market," referring to traditional frames and lenses; once completed, the med-tech transformation "will bear fruit and support the recovery of the share price".
- On competition: "A few big players have made product announcements that generated a lot of interest, but we have not yet seen real competing products on the market."
- "We are really doing everything to regain the (price) position that is rightfully ours... but, at the same time, it will take some time to get there."
- Reuters recalls that EssilorLuxottica has worked with Meta Platforms since 2019 on successive generations of Ray-Ban glasses with cameras, audio and AI features.

### [The Moodie Davitt Report: Alessio Crivelli on blending eyewear craftsmanship with med-tech](https://moodiedavittreport.com/interview-essilorluxotticas-alessio-crivelli-on-blending-eyewear-craftsmanship-with-med-tech-innovation/)

Executive talk · Alessio Crivelli, Managing Director Global Travel Retail · 2025-10-31

- Interview (The Moodie Davitt Report, Hannah Tan, 31 October 2025) with Alessio Crivelli, EssilorLuxottica Managing Director Global Travel Retail and newly appointed TFWA Vice-President Marketing, at the TFWA World Exhibition in Cannes.
- "As our CEO Francesco Milleri often says, EssilorLuxottica is not just an eyewear company - we are a med-tech company"; licensed brands and fashion products "remain essential" and "drive desirability", but another side of the business is "deeply rooted in instruments and optical technology".
- Business split: "Roughly speaking, half of our business is direct-to-consumer, through retail and ecommerce, while the other half is what we call 'Professional Solutions', which serves opticians and wholesalers"; both cover optical and sun.
- The med-tech identity is "a natural progression" of the Essilor-Luxottica merger, which "our CEO envisioned... long before it happened"; integration "has not been easy, but today we're operating at full speed" and enables new categories such as AI eyewear.
- Cannes showcase: Oakley Meta, Nuance Audio, Persol, Prada, Miu Miu and Versace, and the world-first Ray-Ban Automated Retail Solution prototype, an autonomous 24/7 eyewear shopping unit for high-traffic travel environments.
- Travel retail: sunglasses are "underweighted compared to other luxury segments" and "deserve greater visibility and space"; the channel focuses on sun but is testing optical with an in-store lab delivering a complete prescription pair in 30 minutes, including for airport staff.
- Outlook: eyewear "has always been a resilient category" and "the future of affordable luxury in travel retail"; "people may not buy a handbag or a watch, but they'll treat themselves to a pair of sunglasses"; a multi-brand outpost opened with Tasa Meng at Taoyuan airport in May 2025.

### [La República: Ernesto Díaz, President of Professional Solutions for Hispanic America, on Ray-Ban Meta, Nuance Audio and Colombia](https://www.larepublica.co/empresas/ernesto-diaz-presidente-de-professional-solutions-essilorluxottica-hablo-de-las-ray-ban-meta-4128247)

Executive talk · Ernesto Díaz, President of Professional Solutions EssilorLuxottica for Hispanic America · 2025-05-08

- La República (Colombia, Martín Pinzón Lemos, 8 May 2025, Spanish) interview with Ernesto Díaz, President of Professional Solutions EssilorLuxottica for Hispanic America, at the opening of a new showroom in the company's Bogotá offices.
- Global revenue €26,508 million with 6% growth at constant rates (FY2024); Latin America grew 9.7%, and "we are growing at a double-digit pace in Latin America".
- After Brazil and Mexico, Colombia is the region's most important market, and "the Latin market where the professionalism of optometrists is highest... the reference at regional level".
- Customers: "a little more than 5,000 doors registered as customers in Colombia" and "between 30,000 and 40,000 formal customers in Latin America".
- Innovations planned for Colombia within two years: Ray-Ban Meta (Meta AI, voice commands, live translation into the ear, apps for the blind) and Nuance Audio open-ear hearing glasses for mild-to-moderate hearing loss; Bliz, a recent acquisition, was added to cover the sports segment at "quality at a reasonable price".
- Ambition: "We project that our business could double or even triple in a relatively short period of two to three years, and the showroom is a key tool to reach this goal."
- Country manager Felipe Laverde: the Colombian wholesale business serves the optical segment (ophthalmic lenses, frames and specialised instruments) and luxury fashion stores selling sunglasses.

## Questions about EssilorLuxottica

### What does EssilorLuxottica do?

EssilorLuxottica designs, makes and sells prescription lenses, frames, sunglasses, contact lenses, smart glasses and eye-care instruments, through wholesale to opticians and its own stores and e-commerce. It is building a med-tech business with eye clinics and diagnostics.

### What was EssilorLuxottica's revenue in 2025?

FY2025 revenue was €28,491m, +11.2% at constant exchange rates, the first double-digit annual growth in the group's history; adjusted operating profit was €4,459m.

### How many employees does EssilorLuxottica have?

The group has 200,000+ employees in more than 150 countries.

### Who leads EssilorLuxottica?

Francesco Milleri is Chairman and CEO, and Paul du Saillant is Deputy CEO. Delfin, the Del Vecchio family holding chaired by Milleri, is the parent company.

### What is EssilorLuxottica's strategy?

The strategy rests on three pillars: med-tech, wearables and AI through smart eyewear, and the brand portfolio, with a five-year outlook of solid revenue growth at constant exchange rates.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
